Learn about a clinical trial for AML

Because every moment matters.

If you have been newly diagnosed with acute myeloid leukemia (AML), the QuANTUM-First Study may be an option for you. The study is evaluating an investigational medication for AML, given in addition to chemotherapy.

To learn more or to see if you qualify Contact A Study Site

About AML & FLT3-ITD

What is AML with FLT3-ITD?

Acute myeloid leukemia (AML) is a type of cancer that begins in the bone marrow and moves into the bloodstream.

AML is usually fast growing and needs to be treated quickly. Your doctor may have already performed blood and bone marrow tests to determine the type of AML you have, as well as any changes or mutations in your genes.

In some people, having a genetic mutation known as FLT3-ITD makes the disease more difficult to treat and relapse more likely. However, new drugs that target the FLT3-ITD mutation are currently being developed through clinical trials.

The National Comprehensive Cancer Network (NCCN) recommends that you speak with your physician to see if a clinical trial may be right for you.1

For additional information about clinical trials, please see http://www.cancer.gov/about-cancer/treatment/clinical-trials

  • Reference: 1. Panel chair, et. al., NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Acute Myeloid Leukemia Version 1.2015. © 2014 National Comprehensive Cancer Network, Inc. Available at NCCN.org. Accessed February 4, 2016.
To learn more or to see if you qualify Contact A Study Site